Spotlight Therapeutics Raises $36.5 Million Series B To Advance A Pipeline Of Cell-Targeted In Vivo Crispr Gene Editing Biologics
Spotlight Therapeutics Raises $36.5 Million Series B To Advance A Pipeline Of Cell-Targeted In Vivo Crispr Gene Editing Biologics
03/22/22, 11:30 AM
Location
san franciscoMoney raised
$36.5 million
Round Type
series b
Spotlight Therapeutics, Inc. (“Spotlight”), a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, today announced a $36.5M Series B financing to fuel a drive toward the clinic.
Company Info
Location
san francisco, california, united states
Additional Info
Established in mid-2018, Spotlight Therapeutics is a privately held biotechnology company advancing a pipeline of cell-targeted in vivo CRISPR gene editing therapies. Spotlight's proprietary technology platform TAGE (Targeted Active Gene Editors) is a new class of biologics, CRISPR effectors engineered for direct delivery in vivo, to achieve cell-selective therapeutic genome editing. Spotlight's pipeline is advancing its modular programmable CRISPR effectors towards clinical studies in immuno-oncology, ophthalmic diseases and hemoglobinopathies. The company is headquartered in Hayward, California. For more information, please visit www.spotlighttx.com.